Ionization

Photonis' Ion Detection Technology Enables NASA's Key Research of Aurora Phenomenon

Retrieved on: 
Wednesday, March 13, 2024
Ionization, Temperature, Atmosphere, NASA, Weather

On Nov. 8, NASA's Goddard Flight Center's DISSIPATION mission took flight aboard a suborbital, two-stage sounding rocket launched from the Poker Flats Research Range in Fairbanks, Alaska.

Key Points: 
  • On Nov. 8, NASA's Goddard Flight Center's DISSIPATION mission took flight aboard a suborbital, two-stage sounding rocket launched from the Poker Flats Research Range in Fairbanks, Alaska.
  • The launch occurred shortly after midnight and was timed perfectly with the peak of the aurora that morning, which lasted less than half an hour.
  • This knowledge holds significant implications for enhancing our understanding of aurora formation and improving space weather predictions.
  • "We are excited and honored to contribute our advanced Channeltron(TM) Ion Detection Technology to NASA's DISSIPATION Mission.

TOMI Environmental Solutions, Inc. Reports Fourth Quarter and Year End 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024
Hydrogen, MGH, Health, Hydrogen peroxide, Sale, Restaurant, Ionization, RELX, International, Webcast, Education, Harvard University, Food industry, GPO, Holiday, Global Biorisk Advisory Council, Academic Medical Center (Amsterdam), Police, Meat, Completion, Transport, Decontamination, Medication, AALAS, American Biological Safety Association, Research, Hospital, Food, ISSA, BIT, CES, Disinfectant, Conference, Horsepower, Growth, Assistant, MIT, Executive, School, Infection, DARPA, Environmental Health (journal), Raymond Castellani, Health care

FREDERICK, Md., April 01, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its fourth quarter and year end 2023 results.

Key Points: 
  • FREDERICK, Md., April 01, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination utilizing its premier Binary Ionization Technology (BIT) platform through its SteraMist brand of products, today announced its fourth quarter and year end 2023 results.
  • Financial Results for the year ended December 31, 2023, compared to December 31, 2022
    Total net revenue was $7,355,000 compared to $8,338,000.
  • Financial Results for the three months ended December 31, 2023, compared to December 31, 2022
    Total net revenue was $1,528,000 compared to $2,812,000.
  • TOMI will hold a conference call to discuss Fourth Quarter and year end 2023 results at 4:30 p.m.

TOMI Environmental Announces Additional iHP Custom Engineered System Installation Contracted for California

Retrieved on: 
Thursday, February 29, 2024
Hydrogen, ISO, DARPA, Hospital, Restaurant, Hydrogen peroxide, Disinfectant, Annual report, ISPE, Growth, GMP, Ionization, Horsepower, Meat, School, COVID-19, Automation, Decontamination, CES, Police, Laboratory

FREDERICK, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the signing of a new contract for a SteraMist iHP Custom Engineered System (CES) installation with a California-based life sciences company.

Key Points: 
  • FREDERICK, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced the signing of a new contract for a SteraMist iHP Custom Engineered System (CES) installation with a California-based life sciences company.
  • The contracted iHP Custom Engineered System (CES) is valued at approximately $600,000.
  • Following a presentation by Dr. Halden Shane, CEO of TOMI, at an ISPE event hosted by Avid Bioservices, the contractors recognized the benefits of the automated iHP Custom Engineered System showcased in Avid's new facility and brought SteraMist iHP to the customer as an option.
  • Shane, COO of TOMI states, “We’re pleased to announce this new CES contract and look forward to continuing our growth momentum.

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Technology, Biotechnology, Nanotechnology, Health, Molecule, CMO, Infection, Growth, RNA, Phospholipid, Liposome, Solubility, Organization, Absorption, Integration, Therapy, Type, Levidian Nanosystems, Small RNA, Ionization, DNA, Partnership, Creative Biolabs, CMOS, Permeability, Sphingolipid, CDMO, SaRNA, Dicarboxylic acid, Antigen, Research, Emergent, Acquisition, Lipid, Messenger, PEGylation, IBM, Geography, Risk, Fresenius (company), Fujifilm, Triglyceride, Element, MicroRNA, Acuitas Therapeutics, Vaccine

This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Points: 
  • This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.
  • The report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period.
  • Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market.

Turn Biotechnologies' Expanded eTurna™ Delivery Platform Designed to Solve Delivery and Targeting Issues that Challenge Industry

Retrieved on: 
Wednesday, January 3, 2024
Particle size, Messenger, Fibroblast, PEG, Tissue, Macrophage, Ionization, Keratinocyte, Lipid, Blood, Endothelium, Transfection, Cell, Safety, Medicine, Skin, Vaccine

The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.

Key Points: 
  • The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
  • Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
  • "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
  • Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.

Turn Biotechnologies' Expands eTurna™ Delivery Platform to Solve Delivery and Targeting Issues that Challenge Industry

Retrieved on: 
Wednesday, January 3, 2024
Particle size, Messenger, Fibroblast, PEG, Tissue, Macrophage, Ionization, Keratinocyte, Lipid, Blood, Endothelium, Transfection, Cell, Safety, Medicine, Skin, Vaccine

The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.

Key Points: 
  • The proprietary ionizable lipids used in the eTurna™ delivery platform are safer as they are biodegradable, non-toxic and clear the body faster, while providing higher encapsulation capacity and cargo loading.
  • Since the platform can utilize PEG-free stabilizing components, the delivery system minimizes or eliminates immunogenicity associated with PEG lipids currently used in LNPs.
  • "It is designed to enable the delivery of therapies to treat incurable diseases by targeting cells that medicine cannot currently reach.
  • Turn Bio's first drug candidates are focused on treating the skin by targeting specific cells including fibroblasts, endothelial cells and keratinocytes.

TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Second Quarter 2023 Financial Results on August 14, 2023

Retrieved on: 
Tuesday, August 8, 2023
Hydrogen, Ionization, International, DARPA, U.S. Department of Defense Strategy for Operating in Cyberspace, Decontamination, History, School, Hospital, Hydrogen peroxide, Restaurant, Annual report, Police, Disinfectant, Webcast, Meat, Risk management

To participate in the call by phone, dial (877) 545-0320 approximately five minutes prior to the scheduled start time and reference the participant access code 559024 or request the "TOMI Environmental Solutions second quarter earnings call."

Key Points: 
  • To participate in the call by phone, dial (877) 545-0320 approximately five minutes prior to the scheduled start time and reference the participant access code 559024 or request the "TOMI Environmental Solutions second quarter earnings call."
  • To access the live webcast or view the press release, please visit the Investor Relations section of the TOMI website or register at the following link: https://www.webcaster4.com/Webcast/Page/2262/48885 .
  • Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements.
  • As such, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors.

Fujifilm Life Sciences to Showcase Innovative and Comprehensive Solutions Supporting Advanced Therapies at BIO 2023

Retrieved on: 
Thursday, June 1, 2023
Ionization, Vaccine, BIO, Medicine, Therapy, IPSC, Education, Lipid, Boston Convention and Exhibition Center, Traffic barrier, Research, Hasegawa, Fujifilm Diosynth Biotechnologies, Cell, Development, Fujifilm, CDMO, CGMP, Patient, Antibody, Drug discovery, Exhibition, Convention center, Fine chemical, Pharmaceutical industry, Management

“Fujifilm Life Sciences is proud to join BIO 2023 where we will showcase our group company solutions and explore new partnerships with today's leading research organizations and biotech companies.

Key Points: 
  • “Fujifilm Life Sciences is proud to join BIO 2023 where we will showcase our group company solutions and explore new partnerships with today's leading research organizations and biotech companies.
  • Our business portfolio now includes cell culture solutions, research tools such as reagents, investigational drug development, drug delivery solutions, cell therapy development, quality control testing solutions, as well as Bio-CDMO.
  • Through our comprehensive offering, we are uniquely positioned to support and accelerate bringing new therapies to patients in need,” said Yutaka Yamaguchi, corporate vice president and general manager, Life Sciences Business Division, FUJIFILM Corporation, and chairman and chief executive officer, FUJIFILM Irvine Scientific, Inc.
  • Learn more about Fujifilm Life Sciences: https://lifesciences.fujifilm.com/

Eterna Therapeutics and Factor Bioscience Announce New Data on Multi-Cell-Type Therapeutic Approach at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Retrieved on: 
Wednesday, May 17, 2023
Ionization, Spermine, Myelocyte, DNA, Gene, Macrophage, Gene editing, Cancer, Lipid, NK, Research, Cell, Los Angeles Convention Center, Element, Messenger, AAVS1, Acquisition, Patient, ERNA, Blood, Immune system, Entrepreneurship, LNP, Cytotoxicity, IPS, Safety, Society, ROR1, Vaccine, Antibiotics, Eterna

CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, and its discovery partner Factor Bioscience (“Factor”) today announced new data on an iPS cell-derived multi-cell-type therapeutic strategy for solid-tumor targeting, as well as advances in nucleic-acid delivery and targeted gene insertion, in eight poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting, taking place May 16-20, 2023 at the Los Angeles Convention Center.

Key Points: 
  • “This approach has the potential to form the foundation of an entirely new class of cell therapies that could play an important role in treating cancer.
  • In vitro studies with lymphoid and myeloid cells showed synergistic killing of SKOV3 ovarian tumor cells.
  • This methodology has the potential to support the development of engineered cell therapies designed to express therapeutic proteins.
  • The data presented show that the lipids identified may serve as components of next-generation, LNP-based mRNA and gene therapies.

DEFY Teams With John Lenore & Co. to Bring Boost+Immunity Performance Drinks and Alkaline Water to Southern California

Retrieved on: 
Tuesday, April 11, 2023
Mineral, Mission, Water, Immunity, Açaí palm, Dicarboxylic acid, Ionization, Organization, Woman, CO, Super Bowl, Black, Growth, Sambucus

The high performance sports drink also delivers an immunity blend of Elderberry, Acai and more, maximizing the benefits of performance and hydration drinks in one.

Key Points: 
  • The high performance sports drink also delivers an immunity blend of Elderberry, Acai and more, maximizing the benefits of performance and hydration drinks in one.
  • DEFY Alkaline Water was created to meet the growing consumer demand for healthier, great-tasting, purified water, free from impurities and contaminants.
  • Ionized with an alkaline pH 9.5+, infused with vital electrolytes and minerals, DEFY Alkaline Water is optimized for premium taste and supercharged cellular hydration.
  • "Partnering with the leader in Southern California distribution was essential to DEFY’s continued growth,” says DEFY co-founder and President, Megan Bushell.